Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study.

Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiss A, Braun J, Sieper J.

Ann Rheum Dis. 2011 Jun;70(6):1108-10. doi: 10.1136/ard.2010.145946. Epub 2011 Mar 17.

PMID:
21415053
2.
3.

Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.

Saougou I, Markatseli TE, Voulgari PV, Drosos AA.

Joint Bone Spine. 2010 Jul;77(4):325-9. doi: 10.1016/j.jbspin.2010.02.014. Epub 2010 May 8.

PMID:
20452801
4.

Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).

Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J.

Ann Rheum Dis. 2014 May;73(5):817-23. doi: 10.1136/annrheumdis-2013-204248. Epub 2014 Jan 3.

PMID:
24389297
5.

Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.

Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML.

Ann Rheum Dis. 2010 Nov;69(11):2002-8. doi: 10.1136/ard.2009.124446. Epub 2010 May 28.

PMID:
20511613
6.

No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial.

Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, Sieper J.

Ann Rheum Dis. 2007 Mar;66(3):419-21. Epub 2006 Aug 10.

7.

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).

van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.

Arthritis Rheum. 2005 Feb;52(2):582-91.

8.

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.

Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M.

Ann Rheum Dis. 2008 Apr;67(4):547-54. Epub 2007 Oct 5.

PMID:
17921185
9.

Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.

Huang F, Gu J, Zhu P, Bao C, Xu J, Xu H, Wu H, Wang G, Shi Q, Andhivarothai N, Anderson J, Pangan AL.

Ann Rheum Dis. 2014 Mar;73(3):587-94. doi: 10.1136/annrheumdis-2012-202533. Epub 2013 Mar 8.

PMID:
23475983
10.

Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition.

Lekpa FK, Farrenq V, Canouï-Poitrine F, Paul M, Chevalier X, Bruckert R, Bastuji-Garin S, Claudepierre P.

Joint Bone Spine. 2012 Jan;79(1):47-50. doi: 10.1016/j.jbspin.2011.02.018. Epub 2011 Apr 15.

PMID:
21497538
11.

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.

van der Heijde D, Pangan AL, Schiff MH, Braun J, Borofsky M, Torre J, Davis JC Jr, Wong RL, Kupper H, Collantes E; ATLAS Study Group.

Ann Rheum Dis. 2008 Sep;67(9):1218-21. Epub 2007 Dec 4.

12.

Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement.

Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N, Thon A, Borte M, Ganser G, Trauzeddel R, Huppertz HI.

Arthritis Res Ther. 2012 Oct 24;14(5):R230. doi: 10.1186/ar4072.

13.

Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.

Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Horneff G, Huppertz HI, Job-Deslandre C, Loy A, Minden K, Punaro M, Nunez AF, Sigal LH, Block AJ, Nys M, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group.

Arthritis Rheum. 2010 Jun;62(6):1792-802. doi: 10.1002/art.27431.

14.

Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.

Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J.

Ann Rheum Dis. 2008 Mar;67(3):340-5. Epub 2007 Oct 29.

15.

A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.

Inman RD, Maksymowych WP; CANDLE Study Group.

J Rheumatol. 2010 Jun;37(6):1203-10. doi: 10.3899/jrheum.091042. Epub 2010 Mar 15.

PMID:
20231198
16.

Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.

Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji WH.

Ann Rheum Dis. 2008 Mar;67(3):346-52. Epub 2007 Oct 29.

17.

Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.

Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N, van der Heijde D; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.

Arthritis Rheum. 2008 Sep 15;59(9):1270-8. doi: 10.1002/art.24001.

18.

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.

Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, Carcereri-De-Prati R, Kupper H, Kary S.

J Rheumatol. 2009 Apr;36(4):801-8. doi: 10.3899/jrheum.081048. Epub 2009 Feb 27.

PMID:
19273449
19.

Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.

Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J.

Arthritis Rheum. 2003 Aug;48(8):2224-33.

20.

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.

Rheumatology (Oxford). 2005 May;44(5):670-6. Epub 2005 Mar 9.

PMID:
15757965

Supplemental Content

Support Center